This new accolade joins our previous recognitions: - 🏆 2021: Prix de la Région Pays de la Loire at Start West. - 🏆 2022: Award for job creation at Startups & Innovation Day Each award reminds us of all the progress we've made since our launch in 2021.

🚀 [Q1 2024 – recap] Our first 3 months of 2024 have already been marked by several key milestones, enabling us to stay confident about our current scheduled roadmap and to prepare for a global launch. Details : #MedTech #LaFrenchCare

Why can we reach the market faster than most biotech companies and other medtech ? 1️⃣ THE ABILITY TO ADOPT AN AGILE DEVELOPMENT PROCESS 2️⃣ A MORE STREAMLINED REGULATORY APPROVAL PROCESS 3️⃣ THE USE OF BIO-COLLECTIONS #nantes #medtech

Wondering how we're able to process our clinical trials at such a rapid pace? The secret lies in Bio-collections (or Biobanks). These collections of samples (blood, biopsies, etc.) and clinical data, gathered from patients recruited without bias. #MedTech

“BioMAdvanced Diagnostics” and its logo have been successfully registered as Trademarks in the United States of America. Another step in our journey towards delivering great diagnostics solutions to transplanted patients and their clinicians around the world! #medtech #nantes

Why does this matter ? Companies involved in the development and manufacturing of Medical Devices are REQUIRED to have a Certified Quality System in accordance with the ISO 13485 standard.

These tests were conducted independently on two separate days under the supervision of our team. ▶▶▶We are pleased to announce that the product has met all of our expectations. (5/5)

We have now converted the option into a tangible reality by signing the definitive license agreement. This move opens a vast market encompassing 25 million patients globally, grappling with cancer or kidney failure and facing the looming threat of irreversible muscular atrophy.

BioMAdvanced Diagnostics has been selected to join the very selective @Bpifrance CLUB EXCELLENCE. 🚀 Among the 200 K companies supported by Bpifrance, only 2,000 companies, including startups, small and med-size companies, and intermediary size companies (ETI), have been chosen

Last week [Atlanpole Forum] It has become an annual tradition for our CEO, Frederic Pette : attending the @atlanpole Forum. Always invigorating to participate in this event, connect with fellow entrepreneurs, and engage with the entire ecosystem. #Paysdelaloire #frenchtech

Fundraising, product development key milestones, a licence agreement strengthening our IP, big headways on the regulatory front…A new year always gives the opportunity to reflect on the previous year. Here is a full recap of key milestones & achievements